SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-039397
Filing Date
2023-05-15
Accepted
2023-05-15 10:01:33
Documents
14
Period of Report
2023-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea178443-8k_emmauslife.htm   iXBRL 8-K 26640
2 MAY 15, 2023 PRESS RELEASE ea178443ex99-1_emmauslife.htm EX-99.1 36786
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3635
  Complete submission text file 0001213900-23-039397.txt   244121

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE emma-20230515.xsd EX-101.SCH 2998
5 XBRL LABEL FILE emma-20230515_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE emma-20230515_pre.xml EX-101.PRE 22385
8 EXTRACTED XBRL INSTANCE DOCUMENT ea178443-8k_emmauslife_htm.xml XML 3291
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

IRS No.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 23919262
SIC: 2834 Pharmaceutical Preparations